This article was originally published in RAJ Devices
TOPRA appoints FDA's Murray Lumpkin to its advisory council
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
The EU’s upcoming pharma strategy offers an important opportunity for change, according to Medicines for Europe. The off-patent industry body has set out five key issues that should be priorities for the EU Commission.
The EU’s IVD Regulation is going to apply just a year later than the EU’s MDR. Where are the gaps and how can industry manage the IVD notified body shortage?